The controlled studies came back largely null. Microdosing, administered in isolation with no practice context, produced no reliable cognitive enhancement beyond placebo. This was treated as either a scandal or a vindication, depending on who you asked. The more interesting response would have been to notice what the studies were actually testing — and what they weren’t.
What the Controlled Studies Actually Show
The controlled research is, on its own terms, fairly clear. Microdosing does not reliably enhance cognitive performance on standardized measures. Expectancy effects are real and significant: people who believe they’re microdosing report benefits regardless of whether they received an active dose. Long-term safety data remains sparse.
The most methodologically rigorous study to date, Szigeti et al. (2021), a self-blinding citizen science trial, found no significant difference between microdose and placebo groups on any cognitive or wellbeing measure. Other controlled trials have produced similarly underwhelming results for the specific claims Silicon Valley microdosing culture has made: enhanced focus, greater productivity, sharper problem-solving.
This data matters and should be taken seriously. It just doesn’t tell the whole story.
What Gets Lost in the Debunking
The controlled studies necessarily strip microdosing of everything except the molecule. No intention-setting, no journalling, no embodied practice, no community. They measure whether a sub-perceptual dose of psilocybin, taken in isolation, produces measurable cognitive enhancement. When it doesn’t, the conclusion drawn is that microdosing “doesn’t work.”
This frames the question in a way that already misses the point. It’s roughly like testing whether a meditation cushion reduces anxiety and concluding, when the cushion alone does nothing, that meditation doesn’t work.
When microdosing is embedded in a broader framework of attention, intention, and reflection, treated as a contemplative practice rather than a supplement, something different happens. The question shifts from “does this substance work?” to “what does this practice reveal?”
Mindfulness and Molecule
The research on the intersection of psychedelics and contemplative practice points to a genuine synergy. A 2019 study by Smigielski and colleagues found that psilocybin combined with meditation retreat produced significantly greater increases in self-dissolution, positive mood, and social connectedness than either psilocybin or meditation alone. The effects persisted at four-month follow-up.
This makes sense through the lens of enactive cognition. Both psychedelics and contemplative practice work by loosening habitual perceptual structures: the automatic, ego-centered patterns through which experience ordinarily gets organized. Psychedelics do this pharmacologically, by temporarily relaxing the brain’s predictive priors. Contemplative practice does it attentionally, by training the capacity to notice without immediately grasping or interpreting.
When the two are combined, the loosening goes deeper and the capacity to notice what has loosened is more developed. The experience becomes more available for learning, not because the molecule is doing more, but because the practitioner is.
At the microdose level, this dynamic is subtler. A sub-perceptual dose doesn’t produce dramatic perceptual shifts. Within a practice context, it can create a slightly wider aperture of attention: a bit more space between stimulus and response, a gentle foregrounding of sensory detail that might otherwise pass unnoticed. Whether this effect is pharmacological, expectancy-driven, or some combination is, frankly, less important than what you do with it.
Practice Over Protocol
The approach that makes most sense to me builds around attention rather than the substance, learning to notice what changes, what doesn’t, and what that tells you about your relationship to your own experience.
In practice, this means starting each session with an inquiry rather than a performance goal. Not “be more productive” but “what am I not noticing?” It means maintaining a journal that tracks not just mood and energy but subtler things: quality of attention, bodily sensation, relational dynamics, engagement with the living world. Dosing days are paired with somatic practice, time in nature, and movement, because these are the primary vehicle through which subtle attentional shifts become available for reflection. Regular non-dosing periods are built in specifically to observe the difference: what is the substance doing? What is the practice doing? What happens when you bring the same quality of attention without the molecule? Group reflection rounds it out. The practice deepens in relationship, not in isolation.
This is the structure behind Psygaia’s Microdosing with Mindfulness course. The molecule is a tool within a practice. The course is the practice.
The Key Question
The microdosing debate, as currently framed, asks the wrong question. “Does microdosing work?” assumes a supplement model: take the pill, get the result. Under those terms, the answer appears to be: not reliably, and possibly not at all beyond expectancy.
“Does this practice cultivate greater awareness?” is a different question with a different history. Contemplative traditions have been asking versions of it for a long time. Adding a sub-perceptual psychedelic to a well-structured contemplative practice is a specific method within that much larger inquiry into the nature of attention, perception, and how we inhabit the world.
The most interesting microdosing data isn’t about cognitive performance. It’s about the relationship between expectancy, attention, and experience — which is to say, it’s about the mind itself.
